New Lotion Being Studied for Breast Cancer Treatment Side Effect

New Lotion Being Studied for Breast Cancer Treatment Side Effect
Reata Pharmaceuticals Inc, a Texas based company aiming to translate cutting-edge research into breakthrough medicines, has begun to enroll patients in its Phase 2 trial of RTA 408 Lotion (3% and 0.5%) for the prevention and treatment of radiation dermatitis in breast cancer patients receiving radiation therapy. RadDerm Breast Cancer lotionThe majority of patients who undergo radiotherapy suffer from radiation dermatitis, a condition derived from the injuries radiation therapy inflicts upon the cellular structures in the skin, causing pain, ulceration, necrosis, and fibrosis of exposed skin tissues. Radiation dermatitis usually occurs within one to four weeks after the first sessions of radiation therapy and can have a serious impact on a patient’s quality of life, becoming a direct limitation on the radiation dosage prescribed, ultimately affecting cancer progression. Some of the most utilized methods to prevent or minimize radiation dermatitis include moisturizing the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants. Nonetheless, these strategies are often inefficient and the clinical need for a treatment that can safely protect against radiotherapy damages is emergent, since currently there are no approved agents for the prevention of radiation
Subscribe or to access all post and page content.